In this webinar, we will talk about ECM remodeling as the common denominator of all fibro-inflammatory disorders. We will also discuss how ECM turnover may lead to better insight into disease mechanisms and a better biological understanding of individual patients and how we can best use this to guide drug development.
Finally, we delve into endotrophin, a collagen hormone in multi-organ diseases, and endotrophin in HFpEF, a potentially treatable high-risk endotype.
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.